Irish Chamber members, Almac Group and ICON Clinical Research, are among the top 10 Irish companies operating in the U.S. (by numbers employed)
Oct15Mon
Oct15Mon
Oct10Wed
Almac Group Invests to Expand its Existing North Carolina Facility
Continued expansion and investment to support increasing client demand
| Souderton, PA, US, 10 October 2018 – Almac Group, the global contract pharmaceutical development and manufacturing organisation, today announced the completion of an investment in its Durham, North Carolina Clinical Services’ and Diagnostic Services’ capabilities with the opening of a 24,000 sq. ft. building. |
Oct09Tue
 Arran Chemical Company Completes Stage II of its Strategic Plan “ADAPT” Completion of multi-million Euro expansion of manufacturing capacity and deployment of next generation production technologies
|
|
| Athlone, Ireland, 09 October 2018 – as reported in October 2017, Irish based Arran Chemical Company, has responded to client demand for the provision of fine chemicals, pharmaceutical intermediates and advanced building blocks by implementation of its three stage ADAPT (Arran Deploys Advanced Production Technologies) strategy through a multi-million Euro investment. The investment is focused around increasing capacity, further application of its selectAZyme™ biocatalysis technology and implementation of flow chemistry. Arran is proud to announce the completion of Stage II of the strategy and the positive benefit to its global client base. |
Oct02Tue
Almac Group Announces Successful HPRA Inspection at its European Campus
Craigavon, N.I., UK, 02 October 2018 – Almac Group, the global contract pharmaceutical development and manufacturing organisation, is pleased to announce the successful inspection of Almac Pharma Services (Ireland) at its European campus in Dundalk, Ireland, by the Health Products Regulatory Authority (HPRA).
Oct01Mon
Almac Group Launches Global Analytical Services Capability
Craigavon, N.I., 01 Oct 2018 – Almac Group, the global contract development and manufacturing organisation, is delighted to announce its global analytical services capabilities spanning UK, Europe and North America.
Following the successful acquisition of BioClin Research Laboratories in 2017, Almac’s Sciences Business Unit has united its world-class capabilities to form an analytical group which can meet the varying demands required within its clients’ development programs. From 1st October, BioClin will rename under the Almac Sciences brand, further strengthening its offering and presenting a unified platform within the pharmaceutical industry.
